Polycythemia Vera
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
This novel JAK2 inhibitor features reduced off-target suppression of JAK1, JAK3, TYK2, and other kinases.
Initial findings from a phase I study show the compound significantly reduces the need for phlebotomy in patients with PV.
Dr. Grunwald of the Atrium Health Levine Cancer Institute, discusses caring for patients with PV on rare disease day.
Ruxolitinib outperformed best available therapies in achieving durable hematocrit control in patients with polycythemia vera.
Meta-analysis findings support the use of statins in patients with PV and ET to reduce mortality and thrombosis risk.
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
Rusfertide in conjunction with standard therapy is effective in managing polycythemia vera (PV) patients with poorly ...
According to Ciro Roberto Rinaldi and collaborating researchers, CD47, but not calreticulin (CALR), was overexpressed on ...
Treatment with the investigational injectable hepcidin mimetic rusfertide effectively controlled levels of hematocrit ...
Research from at the 12th International Congress on Myeloproliferative Neoplasms shows that rIFNα is superior to HU and ...
A rational and cost-effective treatment for patients with polycythemia vera (PV) might be a combination therapy of ...
Researchers for a study presented at the 12th International Congress on Myeloproliferative Neoplasms used clinical data, ...
Comprehending the full value of ruxolitinib for polycythemia vera (PV) and myelofibrosis (MF) patients is critical for ...
Hematology is the study of diseases related to the blood, including diagnosis, pathology, treatment, prevention, and ...
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.